Literature DB >> 12023608

Patient management by Neoral C(2) monitoring: an international consensus statement.

Gary Levy1, Eric Thervet, John Lake, Kazuharu Uchida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12023608     DOI： 10.1097/00007890-200205151-00003

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  30 in total

1.  Pharmacokinetic and pharmacodynamic analysis of cyclosporine A (CsA) to find the best single time point for the monitoring and adjusting of CsA dose using twice-daily 3-h intravenous infusions in allogeneic hematopoietic stem cell transplantation.

Authors:  Tatsuo Furukawa; Tori Kurasaki-Ida; Masayoshi Masuko; Nobuhiro Tsukada; Kiyoshi Okazuka; Naoko Sato; Toshio Yano; Takashi Abe; Akihito Momoi; Yasuhiko Shibasaki; Masutaka Higashimura; Kaori Karimata; Masato Moriyama; Takashi Kuroha; Jun Takizawa; Ken Toba; Miwako Narita; Ichiro Fuse; Masuhiro Takahashi; Yoshifusa Aizawa
Journal:  Int J Hematol       Date:  2010-06-09       Impact factor: 2.490

2.  Prediction of systemic exposure to cyclosporine in Japanese pediatric patients.

Authors:  Toshiyuki Sakaeda; Kazumoto Iijima; Kandai Nozu; Tsutomu Nakamura; Yuka Moriya; Mika Nishikawa; Atsushi Wada; Noboru Okamura; Masafumi Matsuo; Katsuhiko Okumura
Journal:  J Hum Genet       Date:  2006-09-14       Impact factor: 3.172

3.  Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients.

Authors:  Hélène Bourgoin; Gilles Paintaud; Matthias Büchler; Yvon Lebranchu; Elisabeth Autret-Leca; France Mentré; Chantal Le Guellec
Journal:  Br J Clin Pharmacol       Date:  2005-01       Impact factor: 4.335

Review 4.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 5.  Therapeutic drug monitoring in pediatric renal transplantation.

Authors:  Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2014-04-25       Impact factor: 3.714

6.  Cyclosporin therapeutic drug monitoring--an established service revisited.

Authors:  Raymond G Morris
Journal:  Clin Biochem Rev       Date:  2003-05

7.  Advantages of cyclosporin A using 2-h levels in pediatric kidney transplantation.

Authors:  Lars Pape; Jochen H H Ehrich; Gisela Offner
Journal:  Pediatr Nephrol       Date:  2004-07-10       Impact factor: 3.714

8.  An economic model of 2-hour post-dose ciclosporin monitoring in renal transplantation.

Authors:  Paul A Keown; Bryce Kiberd; Robert Balshaw; Shideh Khorasheh; Carlo Marra; Philip Belitsky; Zoltan Kalo
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  MDR1 polymorphisms effect cyclosporine AUC0-4 values in Behçet's disease patients.

Authors:  Yoshihiko Katsuyama; Masao Ota; Nobuhisa Mizuki; Akiko Ito; Eiichi Okada; Shigeaki Ohno; Tamihide Matsunaga; Hirofumi Fukushima; Shigeru Ohmori
Journal:  Clin Ophthalmol       Date:  2007-09

10.  Utility of C-2 (Cyclosporine) monitoring in postrenal transplant patients: A study in the Indian population.

Authors:  V Thakur; R Kumar; P N Gupta
Journal:  Indian J Nephrol       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.